

October 25, 2022

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division (TEL: 81-3-6838-2803)

Notice Regarding Contract on Distribution Operation of Dovonex[®]Ointment50µg/g, a Topical Treatment of Psoriasis Vulgaris by LEO Pharma K.K.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh; hereinafter, "TOHO HOLDINGS") hereby announces, its wholly owned subsidiary TOHO PHARMACEUTICAL CO., LTD. (Headquarters: Tokyo; President and Representative Director: Akira Umada) and other Kyoso Mirai Group companies were entrusted with distribution operation of the topical treatment of psoriasis vulgaris "Dovonex[®]Ointment50µg/g" (hereinafter, "Dovonex[®]") to be marketed by LEO Pharma K.K. (Country: Denmark; Japanese corporation: Tokyo; President and Japan Representative Director: Kook Hyun Son; hereinafter, "LEO Pharma").

1. Contract background

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

LEO Pharma valued TOHO HOLDINGS's highly-functional logistics system, emergency response system, and contract performance history to launch Dovonex[®] by their own sales in January 2023, and therefore the contract for the distribution of pharmaceuticals with LEO Pharma was made on distribution operation of Dovonex[®].

2. Performance outlook

Impact to consolidated performance is minor.

*About Dovonex[®]

Dovonex[®] Ointment is used to treat psoriasis vulgaris and contains 50 µg/g of calcipotriol (an active vitamin D3 derivative) synthesized by LEO Pharma. It was approved in Denmark in 1990 and has been used as a first-choice drug for psoriasis.